Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAcar, Ozden Ozgun
dc.contributor.authorCetin, Hulya
dc.contributor.authorSemiz, Gurkan
dc.contributor.authorSen, Alaattin
dc.date.accessioned2021-01-16T10:27:47Z
dc.date.available2021-01-16T10:27:47Z
dc.date.issued2020en_US
dc.identifier.issn2450-131X
dc.identifier.uri2224-4018
dc.identifier.urihttps://hdl.handle.net/20.500.12573/429
dc.descriptionThis work was supported by a grant from The Scientific and Technological Research Council of Turkey (TUBITAK 216Z093).en_US
dc.description.abstractBackground and Objective: This study was aimed to elucidate the molecular mechanism of Momordica charantia (MCh), along with a standard drug prednisolone, in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS). Methods: After the induction of the experimental colitis, the animals were treated with MCh (4 g/kg/day) for 14 consecutive days by intragastric gavage. The colonic tissue expression levels of C-C motif chemokine ligand 17 (CCL-17), interleukin (IL)-1 beta, IL-6, IL-23, interferon-gamma (IFN-gamma), nuclear factor kappa B (NFkB), and tumor necrosis factor-alpha (TNF-alpha), were determined at both mRNA and protein levels to estimate the effect of MCh. Besides, colonic specimens were analyzed histopathologically after staining with hematoxylin and eosin. Results: The body weights from TNBS-instigated colitis rats were found to be significantly lower than untreated animals. Also, the IFN-gamma, IL-1 beta, IL-6, Il-23, TNF-alpha, CCL-17, and NF-kB mRNA and protein levels were increased significantly from 1.86-4.91-fold and 1.46-5.50-fold, respectively, in the TNBS-instigated colitis group as compared to the control. Both the MCh and prednisolone treatment significantly reduced the bodyweight loss. It also restored the induced colonic tissue levels of IL-1 beta, IL-6, IFN-gamma, and TNF-alpha to normal levels seen in untreated animals. These results were also supported with the histochemical staining of the colonic tissues from both control and treated animals. Conclusion: The presented data strongly suggests that MCh has the anti-inflammatory effect that might be modulated through vitamin D metabolism. It is the right candidate for the treatment of UC as an alternative and complementary therapeutics.en_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) TUBITAK 216Z093en_US
dc.language.isoengen_US
dc.publisherSCIENDO, BOGUMILA ZUGA 32A, WARSAW, MAZOVIA, POLANDen_US
dc.relation.isversionof10.2478/jtim-2020-0027en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectalternative and complementary therapeuticsen_US
dc.subjectimmunohistochemistryen_US
dc.subjecttrinitrobenzenesulfonic aciden_US
dc.subjectCYP27B1en_US
dc.subjectvitamin D;en_US
dc.subjectinflammatory cytokinesen_US
dc.subjectanti-inflammatoryen_US
dc.subjectinflammatory bowel diseaseen_US
dc.subjectulcerative colitisen_US
dc.subjectMomordica charantiaen_US
dc.titleSuppression of inflammatory cytokines expression with bitter melon (Momordica charantia) in TNBS-instigated ulcerative colitisen_US
dc.typearticleen_US
dc.contributor.departmentAGÜ, Yaşam ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.contributor.authorID0000-0002-2910-6349en_US
dc.contributor.authorID0000-0002-2826-1021en_US
dc.contributor.authorID0000-0003-0276-8542en_US
dc.contributor.authorID0000-0002-8444-376Xen_US
dc.identifier.volumeVolume: 8en_US
dc.identifier.issue3en_US
dc.identifier.startpage177en_US
dc.identifier.endpage187en_US
dc.relation.journalJOURNAL OF TRANSLATIONAL INTERNAL MEDICINEen_US
dc.relation.tubitakTUBITAK 216Z093
dc.relation.publicationcategoryMakale - Uluslararası - Editör Denetimli Dergien_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster